Why the study?
Does a dosage regimen based on pharmacokinetic properties and plasma monitoring improve the clinical benefit of fluoride therapy in osteoporosis?
Does a dosage regimen based on pharmacokinetic properties and plasma monitoring improve the clinical benefit of fluoride therapy in osteoporosis?
Understanding fluoride pharmacokinetics, including bioavailability differences among formulations and food interactions, suggests that individualized dosage regimens and plasma monitoring could improve osteoporosis treatment outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ekstrand et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: